-

Iambic to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following investor conferences:

  • HC Wainwright 2nd Annual AI-Based Drug Discovery Conference - April 2, 2025
  • Needham 24th Annual Healthcare Conference - April 7-10, 2025
  • Piper Sandler Spring Biopharma Symposium - April 16-17, 2025
  • Bank of America Healthcare Conference - May 13-15, 2025

About Iambic

Founded in 2019 and headquartered in San Diego, California, Iambic is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform is delivering high-quality, differentiated therapeutics to the clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai

About Iambic’s AI-Driven Discovery Platform

The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform’s architecture improves data efficiency and allows molecular models to venture across the space of chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

Contacts

media@iambic.ai

Industry:

Iambic

Release Versions
English

Contacts

media@iambic.ai

More News From Iambic

Iambic Announces Pricing of Initial Public Offering

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by Iambic. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other o...

Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic), a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 clinical trial evaluating IAM217, a brain-penetrant, differentiated inhibitor of KIF18A for the potential treatment of triple-negative breast cancer, ovarian cancer, and other...

Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development

SAN DIEGO--(BUSINESS WIRE)--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today unveiled Enchant v3, the next generation of its multimodal transformer model built to advance end-to-end drug discovery and development. Enchant is the ‘brain’ behind Iambic’s molecular superintelligence platform that, when combined with Iambic’s in-house high-throughput experimental chemistry and biology capabilities, can learn from and predict...
Back to Newsroom